Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04122989 · ClinicalTrials.gov registry record · NA
Validation of a Shared Decision-Making Tool for Multiple Sclerosis
A NA study, sponsored by Shared Decision Making Resources.
- Completed
- Registry status
- NA
- Development phase
- 501
- Enrollment target
NCT04122989: Completed NA study, sponsored by Shared Decision Making Resources.
NCT04122989 is a NA study that has completed, run by Shared Decision Making Resources. The registered enrollment target is 501 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04122989, a NA study, has completed, sponsored by Shared Decision Making Resources.
- COMPLETED
- Registry status
- NA
- Development phase
- 501 participants
- Enrollment target
Study Summary
This study evaluates a novel shared decision making tool for multiple sclerosis (MS). Half the patients will be given access to MS-SUPPORT before their scheduled appointment with their healthcare provider, the other half will not be given access.
Primary Outcome
Proportion of MS patients that switch or start a disease modifying therapy (DMT).
Interventions
- OTHER MS-SUPPORT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2019-11-12 |
| Est. Completion | 2021-12-23 |
| Phase | NA |
What the finished NCT04122989 record still lists
NCT04122989 is an interventional study that assigns participants to a tested intervention. The registered 501 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 1 intervention - of which MS-SUPPORT is the first listed.
NCT04122989 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04122989 about?
NCT04122989 is a clinical study titled "Validation of a Shared Decision-Making Tool for Multiple Sclerosis". This study evaluates a novel shared decision making tool for multiple sclerosis (MS). Half the patients will be given access to MS-SUPPORT before their scheduled appointment with their healthcare provider, the other half will not be given access.
What is the current status of trial NCT04122989?
This trial is currently completed. It is a NA study. The enrollment target is 501 participants. The study started on 2019-11-12. Estimated completion is 2021-12-23.
What interventions are being tested in trial NCT04122989?
The interventions under investigation include: MS-SUPPORT (OTHER).
Who is sponsoring clinical trial NCT04122989?
This trial is sponsored by Shared Decision Making Resources, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04122989's enrollment target sits among peer trials
501 193rd of 2000 higher than 1,808 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06934525 · 501 participants · NA
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI